Multistage Nanovehicle Delivery System Based on Stepwise Size Reduction and Charge Reversal for Programmed Nuclear Targeting of Systemically Administered Anticancer Drugs
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The nucleus is the final target of many first‐line chemotherapeutics, but the need to overcome multiple physiological barriers imposes conflicting requirements for size and charge on systemically administered drug delivery systems. Here, an N‐(2‐hydroxypropyl) methacrylamide (HPMA) polymer‐based nanovehicle (PNV) that self‐assembles from anionic HPMA copolymers with charge‐reversal ability and cationic HPMA copolymers with intracellularly detachable subgroups (IDS) is described. The IDS, bearing an anticancer drug and nuclear‐homing cell‐penetrating peptide (R8NLS ligand), is grafted onto the HPMA copolymer via hydrazone linkage. The large, neutrally charged, self‐assembled PNV (≈55 nm) shows good blood persistence and preferential tumor accumulation. After tumoral arrival, the extracellular milieu actuates the disassembly of PNV to linear conjugates (≈10 nm/39 kDa). This first‐stage size reduction exposes R8NLS and allows for deeper tissue penetration and greater cellular internalization. After endocytosis, a second‐stage size reduction occurs when the more acidic endolysosomal pH cleaved the ≈2.4 kDa IDS off the HPMA copolymer backbone and guaranteed the successful nuclear entry via nuclear localization signal assistance. Based on the stepwise size reduction and on‐demand R8NLS exposure, the PNV inhibits growth of HeLa tumors in nude mice by 75%. This work gives important insights into the design of systemic nuclear‐targeted delivery via a multistage size/charge changing way.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Cited by
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
Yang, M., Li, J., Gu, P., & Fan, X. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.12.010 · Cited by 670
Wolfram, J., & Ferrari, M. (2019) · Nano Today · doi:10.1016/j.nantod.2019.02.005 · Cited by 436
The acidic tumor microenvironment: a target for smart cancer nano-theranostics
Feng, L., Dong, Z., Tao, D., Zhang, Y., & Liu, Z. (2018) · National Science Review · doi:10.1093/nsr/nwx062 · Cited by 426
Stimuli responsive drug delivery systems based on nano-graphene for cancer therapy
Yang, K., Feng, L., & Liu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.015 · Cited by 415
Precise nanomedicine for intelligent therapy of cancer
Chen, H., Gu, Z., An, H., Chen, C., Chen, J., Cui, R., Chen, S., Chen, W., Chen, X., Chen, X., et al. (2018) · Science China Chemistry · doi:10.1007/s11426-018-9397-5 · Cited by 409
Stimuli-responsive nanoparticles for targeting the tumor microenvironment
Du, J., Lane, L. A., & Nie, S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.050 · Cited by 382
Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials
Chen, W., Luo, G., & Zhang, X. (2019) · Advanced Materials · doi:10.1002/adma.201802725 · Cited by 373
Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment
Chen, B., Dai, W., He, B., Zhang, H., Wang, X., Wang, Y., & Zhang, Q. (2017) · Theranostics · doi:10.7150/thno.16684 · Cited by 342
Hua, X.-W., Bao, Y.-W., & Wu, F.-G. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b19549 · Cited by 339
Du, J.-Z., Li, H.-J., & Wang, J. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00195 · Cited by 276
Wang, Y., Wei, G., Zhang, X., Xu, F., Xiong, X., & Zhou, S. (2017) · Advanced Materials · doi:10.1002/adma.201605357 · Cited by 203
Dual-pH responsive micelle platform for co-delivery of axitinib and doxorubicin
Xu, X., Li, L., Zhou, Z., Sun, W., & Huang, Y. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.04.060 · Cited by 41
Self-citationTao, J., Ning, W., Lu, W., Wang, R., Zhou, H., Zhang, H., Xu, J., Wang, S., Teng, Z., & Wang, L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.058 · Cited by 10
Advances in 2,3-Dimethylmaleic Anhydride (DMMA)-Modified Nanocarriers in Drug Delivery Systems
Wan, D., Wu, Y., Liu, Y., Liu, Y., & Pan, J. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060809 · Cited by 7
Metadata
- Authors
- Li, L., Sun, W., Zhong, J., Yang, Q., Zhu, X., Zhou, Z., Zhang, Z., & Huang, Y.
- Venue
- Advanced Functional Materials
- Publisher
- Wiley
- Published
- 2015-05-26
- Volume
- 25
- Issue
- 26
- Pages
- 4101-4113
- ISSN
- 1616-301X (ISSN-L)
- 1616-3028
- OpenAlex
- W1515873296
- Cited by
- 134
- References
- 2
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.